Cabot (NYSE:CBT – Get Free Report) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share guidance of 7.400-7.800 for the period, compared to the consensus earnings per share estimate of 7.640. The company issued revenue guidance of -.
Analyst Ratings Changes
CBT has been the subject of a number of analyst reports. JPMorgan Chase & Co. downgraded shares of Cabot from a “neutral” rating to an “underweight” rating and set a $105.00 price objective for the company. in a research report on Monday, November 11th. Mizuho lowered their price objective on shares of Cabot from $122.00 to $110.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $102.00.
Get Our Latest Analysis on CBT
Cabot Trading Down 2.0 %
Cabot (NYSE:CBT – Get Free Report) last posted its quarterly earnings results on Monday, February 3rd. The specialty chemicals company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.74 by $0.02. Cabot had a net margin of 9.51% and a return on equity of 26.60%. As a group, equities analysts forecast that Cabot will post 7.67 EPS for the current year.
Cabot Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, March 14th. Investors of record on Friday, February 28th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, February 28th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 2.03%. Cabot’s dividend payout ratio (DPR) is presently 25.52%.
Cabot announced that its board has authorized a stock repurchase program on Tuesday, December 3rd that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the specialty chemicals company to reacquire shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.
Insider Buying and Selling
In other Cabot news, CAO Lisa M. Dumont sold 865 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $111.74, for a total transaction of $96,655.10. Following the transaction, the chief accounting officer now owns 9,742 shares in the company, valued at approximately $1,088,571.08. This trade represents a 8.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Hobart Kalkstein sold 34,759 shares of Cabot stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $115.23, for a total value of $4,005,279.57. Following the transaction, the executive vice president now owns 50,627 shares in the company, valued at $5,833,749.21. This trade represents a 40.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,190 shares of company stock valued at $5,751,534 over the last 90 days. 3.07% of the stock is currently owned by company insiders.
About Cabot
Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.
Featured Articles
- Five stocks we like better than Cabot
- Are Penny Stocks a Good Fit for Your Portfolio?
- T-Mobile: The Best Wireless Carrier Stock to Own Right Now?
- Top Stocks Investing in 5G Technology
- Boeing: Charting a Course for Recovery and Redemption
- 3 Healthcare Dividend Stocks to Buy
- Top 3 High-Momentum Companies Analysts Are Still Bullish On
Receive News & Ratings for Cabot Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabot and related companies with MarketBeat.com's FREE daily email newsletter.